Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04118764 · ClinicalTrials.gov registry record · NA

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

A NA study of Alzheimer Disease, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT04118764: Completed NA study of Alzheimer Disease, sponsored by Columbia University.

NCT04118764 is a NA study of Alzheimer Disease that has completed, run by Columbia University. The registered enrollment target is 6 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04118764, a NA study of Alzheimer Disease, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test a new technique that may, in the future, help deliver medications to the brain of people with Alzheimer's disease. Participants in this study will undergo a focused ultrasound treatment to the brain, along with Magnetic Resonance Imagine (MRI) and Positron Emission Tomography (PET) scans.

Primary Outcome

The total number of individuals with successful opening of the BBB will be assessed. Blood-brain barrier opening volume will be measured in mm\^3 through contrast-enhanced T1-weighted MRI on the day of the focused ultrasound treatment and 3 days after treatment, to confirm blood-brain barrier restoration.

Conditions Studied

Interventions

  • DRUG Definity
  • DEVICE Neuronavigation-guided single-element focused ultrasound transducer
  • OTHER Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
  • OTHER Positron Emission Tomography (PET)
  • OTHER Amyvid

Study Locations (1)

New York

  • Columbia University Irving Medical Center/NYPH - New York

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2020-08-06
Est. Completion 2022-09-28
Phase NA
Columbia University

958 total trials

What the finished NCT04118764 record still lists

NCT04118764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Definity is the first listed.

NCT04118764 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04118764 about?

NCT04118764 is a clinical study titled "Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound". The purpose of this study is to test a new technique that may, in the future, help deliver medications to the brain of people with Alzheimer's disease. Participants in this study will undergo a focused ultrasound treatment to the brain, along with Magnetic Resonance Imagine (MRI) and Positron Emissi...

What is the current status of trial NCT04118764?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2020-08-06. Estimated completion is 2022-09-28.

What conditions does trial NCT04118764 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT04118764?

The interventions under investigation include: Definity (DRUG), Neuronavigation-guided single-element focused ultrasound transducer (DEVICE), Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents (OTHER), Positron Emission Tomography (PET) (OTHER), Amyvid (OTHER).

Who is sponsoring clinical trial NCT04118764?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04118764 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04118764's enrollment target sits among peer trials

6 300th of 306 higher than 5 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04118764, the US trial registry maintained by the National Library of Medicine. NCT04118764 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.